Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 9/20 | 0.47 |
| ▸ | CDK4 | P11802 | 5/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360699 | 0.94 | HDAC1 (0.54) | HDAC1CDK2CDK4CCNE1MKNK1 | |
| SCHEMBL5795553 | 0.94 | HDAC1 (0.48) | HDAC1CDK2CDK4CCNE1MKNK1 | |
| SCHEMBL413728 | 0.90 | HDAC1 (0.49) | HDAC1CDK2CDK4CCNE1MKNK1 | |
| SCHEMBL409778 | 0.87 | CDK2 (0.57) | HDAC1CDK2CDK4CCNE1CDK19 | |
| SCHEMBL413474 | 0.87 | CDK2 (0.47) | HDAC1CDK2CDK4CCNE1CDK19 | |
| SCHEMBL413670 | 0.85 | CDK19 (0.49) | HDAC1CDK2CDK4CCNE1MKNK1 | |
| SCHEMBL415283 | 0.85 | CDK2 (0.49) | HDAC1CDK2CDK4CCNE1 | |
| SCHEMBL412332 | 0.85 | DYRK3 (0.54) | HDAC1CDK2CDK4CCNE1MKNK1 | |
| SCHEMBL414098 | 0.84 | CDK2 (0.48) | HDAC1CDK2CDK4CCNE1 | |
| SCHEMBL412510 | 0.83 | CDK2 (0.56) | HDAC1CDK2CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | claimed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1546112-A4 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1546112-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004021989-A2 | IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135517-A1 | Imidazolopyridines and methods of making and using the same | ALK, ACVR1, ACVRL1 | HDAC1 2272/4885CDK2 515/4885CDK4 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.